Trials / Withdrawn
WithdrawnNCT04522817
CLBS119 for Repair of COVID-19 Induced Pulmonary Damage
CLBS119 (Autologous Peripheral Blood Derived CD34+ Cells) for Repair of COVID-19 Induced Pulmonary Damage
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Lisata Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This clinical trial will explore the safety and potential efficacy of CLBS119 for the repair of COVID-19 induced pulmonary damage in adults.
Detailed description
This open-label clinical trial will explore the safety and potential efficacy of peripheral blood derived autologous CD34+ cells for the repair of COVID-19 induced pulmonary damage in adults. Eligible subjects will receive a single administration of CLBS119.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CLBS119 | Peripheral blood derived autologous CD34+ cells |
Timeline
- Start date
- 2020-10-05
- Primary completion
- 2021-05-01
- Completion
- 2021-05-01
- First posted
- 2020-08-21
- Last updated
- 2024-10-09
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04522817. Inclusion in this directory is not an endorsement.